Get to know our clinical trials
Trial of amivantamab FOLFIRI compared to cetuximab/bevacizumab FOLFIRI in patients with recurrent, unresectable or metastatic colorectal cancer with KRAS/NRAS and wild-type BRAF who have received prior chemotherapy.
EL OBJETIVO DE ESTE ESTUDIO ES COMPARAR LOS EFECTOS DE AMIVANTAMAB EN COMBINACIÓN CON QUIMIOTERAPIA CONVENCIONAL (FOLFIRI) FRENTE A CETUXIMAB O BEVACIZUMAB EN COMBINACIÓN CON FOLFIRI EN PACIENTES CON CÁNCER COLORRECTAL (CCR) METASTÁSICO QUE CARECEN DE MUTACIONES EN UNOS GENES LLAMADOS KRAS/NRAS Y BRAF. EL TRATAMIENTO CON CETUXIMAB, BEVACIZUMAB Y FOLFIRI YA SE UTILIZA PARA TRATAR A PACIENTES CON SU TIPO DE CÁNCER.
Technical Summary
- Code EudraCT: 2024-513853-66
- Protocol number: 61186372COR3002
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.